Abstract |
GW395058, a PEGylated peptide agonist of the thrombopoietin receptor, stimulates megakaryocytopoiesis and has previously been shown to increase platelet counts in vivo. The pharmacokinetics and pharmacodynamics of GW395058 were characterized using a randomized, crossover study in a large-animal model (dog) of chemotherapy-induced thrombocytopenia. Nine beagle dogs received i.v. carboplatin (350 mg/m(2)) on day 0 and day 28. GW395058 (1.31 mg/kg) (n = 6) or vehicle control (n = 3) was administered on day 1 and day 29 either as an i.v. bolus or s.c. injection. After i.v. administration, peak concentrations of GW395058 occurred rapidly, while the half-life averaged approximately 56 h. Bioavailability (+/- standard deviation) of GW395058 given s.c. was 78.2% (20.9%). GW395058 (i.v. and s.c.) ameliorated the platelet nadir (p = 0.0086) and resulted in a shorter time to recovery compared to the control group. The mean nadir platelet counts following carboplatin administration were 197,000 cells/microl (80,000) for the i.v. GW395058-dose group, 183,000 cells/microl (72,000) for the s.c.-dose group and 71,000 cells/microl (38,000) for the vehicle-alone group. GW395058 reduced the thrombocytopenic effects of carboplatin in dogs. No GW395058-related adverse side effects were observed.
|
Authors | B C Case, M L Hauck, R L Yeager, A H Simkins, M de Serres, V D Schmith, J E Dillberger, R L Page |
Journal | Stem cells (Dayton, Ohio)
(Stem Cells)
Vol. 18
Issue 5
Pg. 360-5
( 2000)
ISSN: 1066-5099 [Print] England |
PMID | 11007920
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- GW395058
- Neoplasm Proteins
- Peptides
- Proto-Oncogene Proteins
- Receptors, Cytokine
- Receptors, Thrombopoietin
- MPL protein, human
- Thrombopoietin
- Carboplatin
|
Topics |
- Animals
- Carboplatin
(toxicity)
- Dogs
- Female
- Injections, Intravenous
- Injections, Subcutaneous
- Leukocyte Count
(drug effects)
- Male
- Metabolic Clearance Rate
- Molecular Mimicry
- Neoplasm Proteins
- Neutrophils
(drug effects)
- Peptides
(blood, pharmacokinetics, pharmacology)
- Platelet Count
(drug effects)
- Proto-Oncogene Proteins
(agonists, physiology)
- Receptors, Cytokine
- Receptors, Thrombopoietin
- Thrombocytopenia
(blood, chemically induced, therapy)
- Thrombopoietin
(physiology)
|